表紙：気管支拡張剤市場、シェア、規模、動向、産業分析レポート：疾患別、投与経路別、薬剤クラス別、作用機序別、地域別、セグメント予測、2023年～2032年

市場調査レポート

商品コード

1297955

気管支拡張剤市場、シェア、規模、動向、産業分析レポート：疾患別、投与経路別、薬剤クラス別、作用機序別、地域別、セグメント予測、2023年～2032年

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032

出版日: 2023年05月23日 | 発行: Polaris Market Research

| ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,250 665,465円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,250 822,045円

レポートPDFを20名様までご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 6,250 978,625円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Polaris Market Research社の最新調査によると、気管支拡張剤の世界市場規模は2032年までに308億8,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

短時間作用型β2アゴニストとコルチコステロイドのような新しい気管支拡張剤の組み合わせを即時緩和のために利用する臨床医や呼吸器専門家の嗜好の高まりと、需要の高まりに対応するためにこれらの薬剤を商品化する主要な業界プレーヤーは、気管支拡張剤の入手可能性と採用を急増させると推定されます。このことは、世界的に高齢化人口の増加と相まって、下部呼吸器管感染症（LRTI）を発症するリスクが高く、市場の成長を増大させると予想されます。

例えば、2023年1月、米国食品医薬品局は、増悪を伴う喘息の治療薬としてAirsupraを承認しました。この革新的な加圧式計量プラットフォームは、アルブテロール／ブデソニドの組み合わせをレスキュー療法として投与し、アルブテロールの追加投与量の維持によって補完します。即効性のある気管支拡張剤に対するニーズの高まりは、主要な呼吸器疾患に対応するための様々な組み合わせの承認取得を促進し、市場の成長を支えています。

呼吸器内科における最近の研究では、小児における気管支収縮症例の増加が示されており、患者数は急速に増加しています。遺伝や不健康な食習慣など様々な要因により、小児は喘息のような長期的な呼吸器疾患にかかりやすくなっています。このことは、世界中の様々なヘルスケア団体による啓発キャンペーンや臨床研究とともに、小児呼吸器治療薬の普及が市場の成長を支えていると推定されます。

例えば、NCBIが2022年8月に発表した調査によると、米国における喘息に罹患している小児の有病率は8.4％と推定され、患者数は600万人以上と推定されました。さらに、小児の66.0％が罹患率の高い重症の喘息に苦しんでいることが判明しました。したがって、既存の患者プールとともに小児患者の増加が、維持療法と重症例における気管支緩和のために気管支拡張剤の需要を促進すると予想されます。

COVID-19が気管支拡張剤市場に与える影響は、コロナウイルスによる呼吸器系の緊急事態に罹患した患者の正常な呼吸を促進するため、好ましいものでした。さらに、この期間に肺炎のような生命を脅かす疾患の発生率が高かったため、気管支拡張剤のような呼吸器系薬剤や支持療法が流入しました。このことは、緊急プロトコルやヘルスケアガイドラインの展開と相まって、呼吸器系の不定愁訴による病院入院の増加により、気管支拡張剤の使用を促進し、パンデミック期間中の市場の成長を強化しました。

気管支拡張剤市場レポートハイライト

COPD分野は、COPD患者の有病率の高さとともに、呼吸器内科における気管支拡張療法の利点に対する認知度の高まりにより、予測期間中に高いCAGRで成長すると予測されます。
経口薬が最大の売上シェアを占めているが、これは気管支収縮エピソードの減少における経口薬の成功率の高さに加え、キサンチン誘導体の支持療法への応用が増加していることが背景にあります。
βアドレナリン作動薬は、他のクラスの気管支拡張剤と比較して効果的な治療プロファイルとともに、呼吸器医療における従来の常識であるため、予測期間中に大きな市場シェアを占めると予想されます。
北米は、大気汚染に起因する気管支炎やその他の呼吸器疾患の発生率の増加により、予測期間中に顕著な成長が見込まれています。

気管支拡張剤- 業界スナップショット
気管支拡張剤市場力学
- 促進要因と機会
  - 喘息とCOPDの発生率の増加
  - 新興国におけるさまざまな成長機会
- 抑制要因と課題
  - 気管支拡張剤に伴う副作用
PESTLE分析
気管支拡張剤業界の動向
バリューチェーン分析
COVID-19感染症の影響分析

第5章世界の気管支拡張剤市場、疾患別

主な調査結果
イントロダクション
喘息
COPD
その他

第6章世界の気管支拡張剤市場、投与経路別

主な調査結果
イントロダクション
吸入可能
オーラル
注入

第7章世界の気管支拡張剤市場、薬剤クラス別

主な調査結果
イントロダクション
ベータアドレナリン作動薬
抗コリン薬
キサンチン誘導体
ホスホジエステラーゼ阻害剤
配合剤

第8章世界の気管支拡張剤市場、作用機序別

主な調査結果
イントロダクション
短時間作用型
長時間作用型

第9章世界の気管支拡張剤市場、地域別

主な調査結果
イントロダクション
- 気管支拡張剤市場評価、地域、2019-2032年
気管支拡張剤市場-北米
- 北米：気管支拡張剤市場、疾患別、2019-2032年
- 北米：気管支拡張剤市場、作用機序別、2019-2032年
- 北米：気管支拡張剤市場、投与経路別、2019～2032年
- 北米：気管支拡張剤市場、薬剤クラス別、2019-2032年
- 気管支拡張剤市場-米国
- 気管支拡張剤市場- カナダ
気管支拡張剤市場- 欧州
- 欧州：気管支拡張剤市場、疾患別、2019～2032年
- 欧州：気管支拡張剤市場、作用機序別、2019～2032年
- 欧州：気管支拡張剤市場、投与経路別、2019～2032年
- 欧州：気管支拡張剤市場、薬剤クラス別、2019～2032年
- 気管支拡張剤市場- 英国
- 気管支拡張剤市場- フランス
- 気管支拡張剤市場- ドイツ
- 気管支拡張剤市場- イタリア
- 気管支拡張剤市場- スペイン
- 気管支拡張剤市場- オランダ
- 気管支拡張剤市場- ロシア
気管支拡張剤市場- アジア太平洋
- アジア太平洋：気管支拡張剤市場、疾患別、2019～2032年
- アジア太平洋：気管支拡張剤市場、作用機序別、2019～2032年
- アジア太平洋：気管支拡張剤市場、投与経路別、2019～2032年
- アジア太平洋：気管支拡張剤市場、薬剤クラス別、2019～2032年
- 気管支拡張剤市場- 中国
- 気管支拡張剤市場- インド
- 気管支拡張剤市場- 日本
- 気管支拡張剤市場- マレーシア
- 気管支拡張剤市場- インドネシア
- 気管支拡張剤市場- 韓国
気管支拡張剤市場-中東およびアフリカ
- 中東およびアフリカ：気管支拡張剤市場、疾患別、2019～2032年
- 中東およびアフリカ：気管支拡張剤市場、作用機序別、2019～2032年
- 中東およびアフリカ：気管支拡張剤市場、投与経路別、2019～2032年
- 中東およびアフリカ：気管支拡張剤市場、薬剤クラス別、2019～2032年
- 気管支拡張剤市場- サウジアラビア
- 気管支拡張剤市場- 南アフリカ
- 気管支拡張剤市場- イスラエル
- 気管支拡張剤市場- アラブ首長国連邦
気管支拡張剤市場-ラテンアメリカ
- ラテンアメリカ：気管支拡張剤市場、疾患別、2019-2032年
- ラテンアメリカ：気管支拡張剤市場、作用機序別、2019-2032年
- ラテンアメリカ：気管支拡張剤市場、投与経路別、2019～2032年
- ラテンアメリカ：気管支拡張剤市場、薬剤クラス別、2019-2032年
- 気管支拡張剤市場- メキシコ
- 気管支拡張剤市場- ブラジル
- 気管支拡張剤市場- アルゼンチン

第10章競合情勢

拡張と買収の分析
- 拡張
- 買収
提携/協業/合意/公開

第11章企業プロファイル

GSK
AstraZeneca
Teva Pharmaceutical
Cipla Inc
Mylan
Merck
Novartis
Boehringer Ingelheim
Sun Pharmaceutical Industries
Glenmark Pharmaceuticals Limited

図表

List of Tables

Table 1 Global Bronchodilators Market, by Disease, by Region, 2019-2032 (USD Billion)
Table 2 Global Bronchodilators Market, by Route Of Administration, by Region, 2019-2032 (USD Billion)
Table 3 Global Bronchodilators Market, by Drug Class, by Region, 2019-2032 (USD Billion)
Table 4 Global Bronchodilators Market, by Mode of Action, by Region, 2019-2032 (USD Billion)
Table 5 Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
Table 6 North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 7 North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 8 North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 9 North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 10 U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 11 U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 12 U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 13 U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 14 Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 15 Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 16 Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 17 Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 18 Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 19 Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 20 Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 21 Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 22 Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 23 Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 24 Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 25 Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 26 France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 27 France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 28 France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 29 France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 30 UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 31 UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 32 UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 33 UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 34 Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 35 Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 36 Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 37 Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 38 Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 39 Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 40 Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 41 Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 42 Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 43 Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 44 Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 45 Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 46 Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 47 Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 48 Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 49 Russia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 50 Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 51 Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 52 Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 53 Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 54 China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 55 China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 56 China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 57 China: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 58 Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 59 Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 60 Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 61 Japan: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 62 India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 63 India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 64 India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 65 India: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 66 Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 67 Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 68 Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 69 Indonesia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 70 Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 71 Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 72 Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 73 Malaysia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 74 South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 75 South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 76 South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 77 South Korea: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 78 Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 79 Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 80 Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 81 Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 82 Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 83 Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 84 Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 85 Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 86 Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 87 Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 88 Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 89 Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 90 Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 91 Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 92 Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 93 Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 94 Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 95 Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 96 Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 97 Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 98 UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 99 UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 100 UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 101 UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 102 Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 103 Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 104 Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 105 Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 106 South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 107 South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 108 South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 109 South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
Table 110 Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
Table 111 Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
Table 112 Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
Table 113 Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)

List of Figures

Figure 1. Global Bronchodilators Market, 2019-2032 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up Mode of Action
Figure 4. Market by Geography
Figure 5. Porter's Five Forces
Figure 6. Market by Disease
Figure 7. Global Bronchodilators Market, by Disease, 2021 & 2030 (USD Billion)
Figure 8. Market by Mode of Action
Figure 9. Global Bronchodilators Market, by Mode of Action, 2021 & 2030 (USD Billion)
Figure 10. Market by Route Of Administration
Figure 11. Global Bronchodilators Market, by Route Of Administration, 2021 & 2030 (USD Billion)
Figure 12. Market by Drug Class
Figure 13. Global Bronchodilators Market, by Drug Class, 2021 & 2030 (USD Billion)

Product Code: PM3204

The global bronchodilators market size is expected to reach USD 30.88 billion by 2032, according to a new study by Polaris Market Research. The report "Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing preference of clinicians and respiratory experts on utilizing novel bronchodilator combinations such as short-acting beta 2 agonists along with corticosteroids for immediate relief along with key industry players commercializing these drugs to cater the rising demand is estimated to surge availability and adoption of bronchodilators. This coupled with rise in ageing population globally at a higher risk of developing Lower Respiratory Tract Infections (LRTI) are anticipated to augment the growth of the market.

For instance, in January 2023, the U.S. Food and Drug administration approved Airsupra for the therapy of Asthma with exacerbations. The innovative pressurized metering platform delivers the combination albuterol/budesonide as a rescue therapy, supplemented by maintenance of additional albuterol dose. The increasing need of quick acting bronchodilators is promoting key players in gaining approvals for various combinations to cater major respiratory disorders thereby supporting the growth of the market.

Recent studies in respiratory medicine have shown increasing occurrence of bronchoconstriction cases in children which is growing rapidly among the patient pool. Various factors such as genetics, unhealthy food habits, among others are making of pediatrics susceptible to long term respiratory conditions such as Asthma. This along with awareness campaigns and clinical research by various healthcare bodies around the globe, promoting pediatric respiratory medication is estimated to support the growth of the market.

For instance, a research study published by the NCBI, in August 2022, the prevalence of children suffering from Asthma in the U.S. was estimated to be 8.4%, estimated over 6 million patient population. Moreover, 66.0% of children were found to be suffering from severe cases of Asthma with a high morbidity rate. Therefore, the increasing presence of pediatric patients along with the existing patient pool is anticipated to drive the demand for bronchodilators owing to maintenance therapy and bronchial alleviation in cases of severity.

The impact of COVID-19 on the bronchodilator market was favorable due facilitation of normal breathing for patients affected by the corona virus induced respiratory emergencies. Moreover, high incidence rates of life threatening diseases such as pneumonia during the period demanded an inflow of respiratory medications and supportive therapies such as bronchodilation. This coupled with deployment of emergency protocols and healthcare guidelines, increasing hospital admissions with respiratory complaints promoted the use of bronchodilators thereby bolstering the growth of the market during the pandemic.

Bronchodilators Market Report Highlights

COPD segment is anticipated to grow at a high CAGR over the forecast period owing to rising awareness of bronchodilation therapy benefits in respiratory medicine along with high prevalence of COPD among patient population.

Oral accounted for largest revenue share which is accelerated by the higher success rates of oral drugs in reducing bronconstriction episodes along increasing applications of Xanthine derivatives in supportive therapies.

Beta-Adrenergics is expected to hold the significant market share over the forecast period due to its conventional wisdom in respiratory medicine along with effective treatment profile as compared to other classes of bronchodilators.

North America is expected to grow prominently over the projected period owing to increasing incidence of bronchitis and other respiratory disorders triggered due to air pollution.

The global players in the market include GSK, AstraZeneca, Teva Pharmaceutical, Cipla Inc., Mylan, Merck, Novartis, Boehringer Ingelheim, Sun Pharmaceutical, Glenmark Pharmaceuticals.

Polaris Market Research has segmented the bronchodilators market report based by disease, by route of administration, by drug class, by mode of action and region:

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

Asthma
COPD
Others

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Inhalable
Oral
Injection

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Beta-Adrenergics
Anticholinergics
Xanthine Derivatives
Phosphodiesterase Inhibitors
Combination Drugs

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

Short Acting
Long Acting

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Bronchodilators Market Insights

4.1. Bronchodilators - Industry Snapshot
4.2. Bronchodilators Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rise in incidence of asthma and COPD
  - 4.2.1.2. Various growth opportunities in emerging economies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Side effects associated with bronchodilators
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Bronchodilators Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Bronchodilators Market, by Disease

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
5.3. Asthma
- 5.3.1. Global Bronchodilators Market, by Asthma, by Region, 2019-2032 (USD Billion)
5.4. COPD
- 5.4.1. Global Bronchodilators Market, by COPD, by Region, 2019-2032 (USD Billion)
5.5. Others
- 5.5.1. Global Bronchodilators Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Bronchodilators Market, by Route Of Administration

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
6.3. Inhalable
- 6.3.1. Global Bronchodilators Market, by Inhalable, by Region, 2019-2032 (USD Billion)
6.4. Oral
- 6.4.1. Global Bronchodilators Market, by Oral, by Region, 2019-2032 (USD Billion)
6.5. Injection
- 6.5.1. Global Bronchodilators Market, by Injection, by Region, 2019-2032 (USD Billion)

7. Global Bronchodilators Market, by Drug Class

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
7.3. Beta-Adrenergics
- 7.3.1. Global Bronchodilators Market, by Beta-Adrenergics, by Region, 2019-2032 (USD Billion)
7.4. Anticholinergics
- 7.4.1. Global Bronchodilators Market, by Anticholinergics, by Region, 2019-2032 (USD Billion)
7.5. Xanthine Derivatives
- 7.5.1. Global Bronchodilators Market, by Xanthine Derivatives, by Region, 2019-2032 (USD Billion)
7.6. Phosphodiesterase Inhibitors
- 7.6.1. Global Bronchodilators Market, by Phosphodiesterase Inhibitors, by Region, 2019-2032 (USD Billion)
7.7. Combination Drugs
- 7.7.1. Global Bronchodilators Market, by Combination Drugs, by Region, 2019-2032 (USD Billion)

8. Global Bronchodilators Market, by Mode of Action

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
8.3. Short Acting
- 8.3.1. Global Bronchodilators Market, by Short Acting, by Region, 2019-2032 (USD Billion)
8.4. Long Acting
- 8.4.1. Global Bronchodilators Market, by Long Acting, by Region, 2019-2032 (USD Billion)

9. Global Bronchodilators Market, by Geography

9.1. Key findings
9.2. Introduction
- 9.2.1. Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
9.3. Bronchodilators Market - North America
- 9.3.1. North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
- 9.3.2. North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
- 9.3.3. North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
- 9.3.4. North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.5. Bronchodilators Market - U.S.
  - 9.3.5.1. U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.3.5.2. U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.3.5.3. U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.3.5.4. U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.6. Bronchodilators Market - Canada
  - 9.3.6.1. Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.3.6.2. Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.3.6.3. Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.3.6.4. Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4. Bronchodilators Market - Europe
- 9.4.1. Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
- 9.4.2. Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
- 9.4.3. Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
- 9.4.4. Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.5. Bronchodilators Market - UK
  - 9.4.5.1. UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.5.2. UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.5.3. UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.5.4. UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.6. Bronchodilators Market - France
  - 9.4.6.1. France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.6.2. France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.6.3. France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.6.4. France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.7. Bronchodilators Market - Germany
  - 9.4.7.1. Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.7.2. Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.7.3. Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.7.4. Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.8. Bronchodilators Market - Italy
  - 9.4.8.1. Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.8.2. Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.8.3. Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.8.4. Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.9. Bronchodilators Market - Spain
  - 9.4.9.1. Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.9.2. Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.9.3. Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.9.4. Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.10. Bronchodilators Market - Netherlands
  - 9.4.10.1. Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.10.2. Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.10.3. Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.10.4. Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.11. Bronchodilators Market - Russia
  - 9.4.11.1. Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.4.11.2. Russia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.4.11.3. Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.4.11.4. Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5. Bronchodilators Market - Asia Pacific
- 9.5.1. Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
- 9.5.2. Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
- 9.5.3. Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
- 9.5.4. Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.5. Bronchodilators Market - China
  - 9.5.5.1. China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.5.2. China.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.5.3. China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.5.4. China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.6. Bronchodilators Market - India
  - 9.5.6.1. India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.6.2. India.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.6.3. India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.6.4. India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.7. Bronchodilators Market - Japan
  - 9.5.7.1. Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.7.2. Japan.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.7.3. Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.7.4. Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.8. Bronchodilators Market - Malaysia
  - 9.5.8.1. Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.8.2. Malaysia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.8.3. Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.8.4. Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.9. Bronchodilators Market - Indonesia
  - 9.5.9.1. Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.9.2. Indonesia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.9.3. Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.9.4. Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.10. Bronchodilators Market - South Korea
  - 9.5.10.1. South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.5.10.2. South Korea.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.5.10.3. South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.5.10.4. South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6. Bronchodilators Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
- 9.6.2. Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
- 9.6.3. Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
- 9.6.4. Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.5. Bronchodilators Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.6.5.2. Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.6.5.3. Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.6.5.4. Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.6. Bronchodilators Market - South Africa
  - 9.6.6.1. South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.6.6.2. South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.6.6.3. South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.6.6.4. South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.7. Bronchodilators Market - Israel
  - 9.6.7.1. Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.6.7.2. Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.6.7.3. Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.6.7.4. Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.8. Bronchodilators Market - UAE
  - 9.6.8.1. UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.6.8.2. UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.6.8.3. UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.6.8.4. UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.7. Bronchodilators Market - Latin America
- 9.7.1. Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
- 9.7.2. Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
- 9.7.3. Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
- 9.7.4. Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.5. Bronchodilators Market - Mexico
  - 9.7.5.1. Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.7.5.2. Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.7.5.3. Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.7.5.4. Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.6. Bronchodilators Market - Brazil
  - 9.7.6.1. Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.7.6.2. Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.7.6.3. Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.7.6.4. Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.7. Bronchodilators Market - Argentina
  - 9.7.7.1. Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  - 9.7.7.2. Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  - 9.7.7.3. Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  - 9.7.7.4. Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. GSK
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. AstraZeneca
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Teva Pharmaceutical
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Cipla Inc
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Mylan
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Merck
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Novartis
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Boehringer Ingelheim
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Sun Pharmaceutical Industries
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Glenmark Pharmaceuticals Limited
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development

気管支拡張剤市場、シェア、規模、動向、産業分析レポート：疾患別、投与経路別、薬剤クラス別、作用機序別、地域別、セグメント予測、2023年～2032年

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032

気管支拡張剤市場レポートハイライト

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界の気管支拡張剤市場に関する洞察

第5章世界の気管支拡張剤市場、疾患別

第6章世界の気管支拡張剤市場、投与経路別

第7章世界の気管支拡張剤市場、薬剤クラス別

第8章世界の気管支拡張剤市場、作用機序別

第9章世界の気管支拡張剤市場、地域別

第10章競合情勢

第11章企業プロファイル

List of Tables

List of Figures

Bronchodilators Market Report Highlights

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Bronchodilators Market Insights

5. Global Bronchodilators Market, by Disease

6. Global Bronchodilators Market, by Route Of Administration

7. Global Bronchodilators Market, by Drug Class

8. Global Bronchodilators Market, by Mode of Action

9. Global Bronchodilators Market, by Geography

10. Competitive Landscape

11. Company Profiles

気管支拡張剤市場、シェア、規模、動向、産業分析レポート：疾患別、投与経路別、薬剤クラス別、作用機序別、地域別、セグメント予測、2023年～2032年

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032

気管支拡張剤市場レポートハイライト

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の気管支拡張剤市場に関する洞察

第5章 世界の気管支拡張剤市場、疾患別

第6章 世界の気管支拡張剤市場、投与経路別

第7章 世界の気管支拡張剤市場、薬剤クラス別

第8章 世界の気管支拡張剤市場、作用機序別

第9章 世界の気管支拡張剤市場、地域別

第10章 競合情勢

第11章 企業プロファイル

List of Tables

List of Figures

Bronchodilators Market Report Highlights

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Bronchodilators Market Insights

5. Global Bronchodilators Market, by Disease

6. Global Bronchodilators Market, by Route Of Administration

7. Global Bronchodilators Market, by Drug Class

8. Global Bronchodilators Market, by Mode of Action

9. Global Bronchodilators Market, by Geography

10. Competitive Landscape

11. Company Profiles

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界の気管支拡張剤市場に関する洞察

第5章世界の気管支拡張剤市場、疾患別

第6章世界の気管支拡張剤市場、投与経路別

第7章世界の気管支拡張剤市場、薬剤クラス別

第8章世界の気管支拡張剤市場、作用機序別

第9章世界の気管支拡張剤市場、地域別

第10章競合情勢

第11章企業プロファイル